Interim report
Page 1
RNS Number : 0916PSmith & Nephew Plc04 August 2026 Smith+Nephew Second Quarter and First Half 2026 Results Strong H1 profit growth, on-track to meet trading profit, freecash flow and ROIC guidance despite softer revenue growth 4 August 2026 27 June 28 June Reported Underlying 2026 2025 growth growth $m $m % % Second Quarter Results Revenue 1,597 1,553 2.8 1.6 Half Year Results Revenue 3,097 2,961 4.6 2.3 Operating profit 448 429 4.3 Operating profit margin (%) 14.5 14.5 EPS (cents) 35.6 33.5 6.2 Cash generated from operations 605 568 6.9 Trading profit 566 523 8.1 Trading profit margin (%) 18.3 17.7 EPSA (cents) 47.7 42.9 11.0 Free cash flow 231 244 (5.2) (Financial Performance - H1 and Q2 2026 results unless otherwise stated, growth % and commentary are given on an underlying basis as defined on page 9 and are for the half and quarter ended 27 June 2026. In Q2 2026, the currency tailwind on reported growth versus underlying growth primarily reflected strength of the Euro and Australian dollar.) Q2 Highlights · Q2 revenue was $1,597 million, with underlying revenue growth of 1.6%, and reported revenue growth of 2.8% including a 120bps FX tailwind · Q2 performance driven by continued strength in Sports Medicine offset by softness in US Orthopaedics and Advanced Wound Bioactives · Multiple product platforms delivering double-digit or higher growth including CATALYSTEM◊, AETOS◊, Q-FIX◊, REGENETEN◊, CARTIHEAL◊ AGILI-C◊, FASTSEAL◊ and LEAF◊ · High cadence of new product launches, expansions and approvals including TESSA◊ Spatial Surgery System H1 Highlights · H1 revenue was $3,097 million, with underlying revenue growth of 2.3%. Reported growth of 4.6% was after 230bps FX tailwind. Growth reflected one fewer trading day versus the prior year, with underlying revenue growth of 3.1% on an average daily sales (ADS) basis · Strong trading profit growth driven by a step-up in forecast efficiency savings, while tariff refunds fully offset the forecast tariff headwind. Trading profit was $566 million, up 8.1% on a reported basis including 90bps dilution from the acquisition of Integrity Orthopaedics. Trading profit margin up 60bps to 18.3%. Operating profit increased 4.3% on a reported basis to $448 million · Adjusted earnings per share ('EPSA') up 11.0% to 47.7¢ and basic earnings per share ('EPS') up 6.2% to 35.6¢ · Continued strong cash generation. H1 free cash flow $13 million lower than H1 2025 includes a $51 million increase in capex relating largely to the construction of our new UK Wound factory and IT upgrades. This does not repeat in H2 when cash generation is expected to be stronger versus H2 2025
Page 2
· Building on our strong cash generation and balance sheet, a $500 million share buyback was announced in May, with $216 million settled as at 3 August. Adjusted net debt/EBITDA leverage ratio at H1 2026 was 1.8x · Interim dividend increased by 4.0% to 15.6¢ per share Anticipated growth in full year revenue reduced from around 6% to around 4%; tradingprofit, free cash flow and adjusted ROIC guidance unchanged · We expect second half revenue growth to be in the range of 5.0% to 5.5%, a step up on the first half, driven by multiple factors, including: o In Sports Medicine, continued momentum across segments including strong growth in REGENETEN and FASTSEAL o In Advanced Wound Management, stabilisation in US skin substitutes, a return to growth in SANTYL◊, expansion of the European launch of ALLEVYN◊ COMPLETE CARE, the launch of next-generation LEAF, and investment behind PICO◊ o In Orthopaedics, improving trajectory in US Knee Implants driven by LEGION◊ MS and the launch of the cementless version of LANDMARK◊, as well as a return to growth in US Hip Implants following increased CATALYSTEM set deployment o An extra trading day in the fourth quarter · Despite the revised full year revenue guidance, we continue to expect around 8% trading profit growth excluding acquisitions (around $1.3 billion post-acquisition of Integrity Orthopaedics), around $800 million free cash flow, and more than 10% adjusted ROIC (excluding impact of Integrity Orthopaedics) o We now anticipate the year-on-year impact of tariffs will be broadly neutral to trading profit net of refunds o The headwind from skin substitutes is expected to be towards the upper end of the previously guided $20 to $40 million range o We expect to be able to offset the impact on trading profit of lower revenue growth through an additional $50 million in efficiency savings identified for 2026, taking total savings to around $200 million for the year Deepak Nath, Chief Executive Officer, said: "The Group navigated some challenges in the second-quarter. Sports Medicine continued to performstrongly, but Orthopaedics was impacted by temporary headwinds in US Hip Implants and ongoingchallenges in US Knee Implants ahead of new product introductions. We also saw softer-than-expected performance from SANTYL within Bioactives, although we expect the product to return togrowth in the third quarter. "The changes implemented through our 12-Point Plan have made the Group more resilient and betterable to respond to such challenges. As a result, despite slower-than-expected revenue growth, wedelivered a strong first-half profit performance primarily driven by a step-up in forecast efficiencysavings. "Importantly, that improved resilience gives us confidence in our ability to deliver our full-yearguidance for trading profit, free cash flow and return on invested capital. The updated revenueguidance reflects both the soft first half and our expectation for a step-up in the second half.Orthopaedics is not where we want it to be, but we expect growth to accelerate as we fill portfoliogaps, starting later this year and continuing into 2027. We have already made progress onOrthopaedics trading profit margin ahead of these launches. We remain focused on capital allocationand opportunities to enhance shareholder returns." Second quarter 2026 trading update Our second quarter revenue was $1,597 million (Q2 2025: $1,553 million), reflecting underlyingrevenue growth of 1.6%, which was lower than we anticipated. Reported revenue growth was 2.8%,including 120bps tailwind from foreign exchange. The second quarter of 2026 comprised 63 tradingdays, in line with the same period of 2025. Sports Medicine & ENT 27 June 28 June Reported Underlying Acquisitions Currency Consolidated revenue by 2026 2025 growth growth /disposals impact
Page 3
business unit by product $m $m % % % % Sports Medicine & ENT 527 479 10.0 8.6 - 1.4 Sports Medicine Joint Repair 293 262 11.8 10.6 - 1.2 Arthroscopic Enabling Technologies 178 161 10.6 8.8 - 1.8 ENT (Ear, Nose and Throat) 56 56 (0.3) (1.6) - 1.3 Our Sports Medicine business unit continued to deliver robust revenue growth, building on thecontinued momentum in the franchise, driven by our differentiated portfolio, including new productlaunches and recent acquisitions. Sports Medicine Joint Repair growth was led by shoulder repair, including double-digit growth fromour REGENETEN Bioinductive Implant and the Q-FIX KNOTLESS All-Suture Anchor. The CARTIHEALAGILI-C Cartilage Repair Implant, acquired in 2024, delivered strong growth as we continue toexpand availability, including completing first cases in Europe and Australia. The integration of Integrity Orthopaedics, and its Tendon Seam◊ technology for rotator cuff repair, acquired at the startof the year, is progressing well. Arthroscopic Enabling Technologies performance was driven by double-digit growth both from our WEREWOLF◊ FASTSEAL 6.0 Hemostasis Wand and our service business. We again saw strongdemand in China where the Volume-Based Procurement (VBP) process has been delayed and whichwe now expect to be implemented in the second half of 2026. ENT underlying revenue decline was as expected and reflected continued actions in China to reducechannel inventory ahead of the expected VBP process in this segment. This offset the goodperformance across all other regions, including double-digit growth in Other Established Markets and Emerging Markets and from the ARIS◊ COBLATION◊ Turbinate Reduction Wand and HALO◊ Wand fortonsillectomy and adenoidectomy. Advanced Wound Management 27 June 28 June Reported Underlying Acquisitions Currency Consolidated revenue by 2026 2025 growth growth /disposals impact business unit by product $m $m % % % % Advanced Wound Management 456 459 (0.7) (2.1) - 1.4 Advanced Wound Care 204 192 6.1 3.7 - 2.4 Advanced Wound Bioactives 144 165 (12.5) (12.7) - 0.2 Advanced Wound Devices 108 102 5.5 3.8 - 1.7 Advanced Wound Management performance reflected continued headwinds in Advanced WoundBioactives and strong comparative periods in both Advanced Wound Bioactives and AdvancedWound Devices. Advanced Wound Care growth was driven by our foam portfolio led by the recently launchedALLEVYN COMPLETE CARE. The US launch is going well and during the quarter we initiated theEuropean launch, with good early traction in Germany. We also delivered double-digit growth fromALLEVYN AG, our absorbent antimicrobial foam dressing. Advanced Wound Bioactives revenue decline was driven by the changes to reimbursement rulesfor skin substitutes which took effect at the start of 2026 as well as by a soft quarter for SANTYLfollowing a strong Q1. In skin substitutes, while there was a sequential improvement from the firstquarter, the impact of the reimbursement reset continued to drive a decline in both volumes andpricing in non-surgical settings, particularly in mobile where we have limited exposure. Despite thesenear-term dynamics, we continue to believe in the long-term fundamentals of the skin substitutesegment beyond this transition year, and remain well-positioned as market conditions normalise. Advanced Wound Devices performance included double-digit growth from the LEAF PatientMonitoring System, a key component of our pressure injury prevention strategy. Our PICO single- use Negative Pressure Wound Therapy (NPWT) and RENASYS◊ traditional NPWT both performedstrongly in Emerging Markets, as we continue to expand geographically. PICO sales in OtherEstablished Markets were impacted by doctor strikes in Spain in the surgical sector and the timingof tenders. In the US, sales of RENASYS continue to be soft in the acute care channel, whileperformance in the post-acute channel remained strong. Orthopaedics 27 June 28 June Reported Underlying Acquisitions Currency Consolidated revenue by 2026 2025 growth growth /disposals impact business unit by product $m $m % % % % Orthopaedics 614 615 (0.2) (1.0) - 0.8 Knee Implants 247 257 (3.8) (4.3) - 0.5 Hip Implants 165 162 1.4 0.5 - 0.9 Other Reconstruction 36 35 2.0 0.8 - 1.2 Trauma & Extremities 166 161 3.5 2.4 - 1.1 Our Orthopaedics business unit revenue declined by -1.0% on an underlying basis (reported decline-0.2%) in the second quarter, reflecting a number of factors in the US including the ongoing issues inKnee Implants ahead of new product launches and temporary headwinds in Hips Implants.Additionally, US Hip Implants, Knee Implants outside the US and Other Reconstruction all faced strongcomparative periods. US Knee Implants revenue declined -7.2% on both an underlying and reported basis, a modestimprovement on Q1, as expected. As with recent quarters, performance reflected the continuingand deliberate portfolio and capital discipline, combined with an ongoing market shift towardscementless, which continues to influence performance in the near term. The sequentialimprovement was driven by strong uptake of LEGION MS and continued double-digit growth fromLEGION CONCELOC, our cementless offering. LEGION MS now represents almost 20% of ourLEGION mix and is enhancing the competitiveness of our installed base. Looking ahead, we
Page 4
continue to expect improvement through the year, driven by increased LEGION MS set deploymentsin the second half. This will remain the main contributor to momentum ahead of launch of our newkinematic LANDMARK Knee System, with the cementless version expected in the third quarter of2026. Following four consecutive quarters of above market growth, US Hip Implants revenue declined-1.5% on both an underlying and reported basis. The CATALYSTEM Primary Hip System is stillgrowing strongly, although Q2 was impacted by some delay in set deployments and an increasingproportion of retentions versus competitive conversions. We expect the segment to return to growthfor the remainder of the year driven by increased CATALYSTEM set deployment, and as CATALYSTEMmoves into its third-year post-launch, we anticipate it continuing to drive a healthy growth rate inUS Hip Implants, albeit at a more moderate level than during the early launch phase. Outside the US, Knee Implants declined -1.4% (reported decline -0.3%) reflecting the impact of alarge tender order in the Middle East in the prior year which did not repeat. Hip Implants delivered underlying revenue growth of 3.0% (reported growth 5.2%) outside the US, led by the POLAR3◊ Total Hip System, as well as strong performance in Japan where we have recently launchedCATALYSTEM. Other Reconstruction underlying revenue growth reflected the comparator period as well as contract mix. We delivered double digit growth in CORI◊ Surgical System installations globally. Trauma & Extremities performance was driven by the EVOS◊ Plating System and IM Nails as wellas strong double-digit growth from the recently launched AETOS Shoulder System. Performance by region 27 June 28 June Reported Underlying Acquisitions Currency Consolidated revenue by 2026 2025 growth growth /disposals impact geography $m $m % % % % US 816 827 (1.2) (1.3) - 0.1 Other Established Markets(i) 489 470 4.0 1.7 - 2.3 Total Established Markets 1,305 1,297 0.6 (0.2) - 0.8 Emerging Markets 292 256 13.7 10.6 - 3.1 Total 1,597 1,553 2.8 1.6 - 1.2 (i) Other Established Markets are Europe, Japan, Australia, Canada and New Zealand The US revenue decline reflected performance in Orthopaedics and Advanced Wound Bioactives. Other Established Markets performance was led by growth from Canada and Australia & New Zealand, continuing the good momentum seen in the first quarter. Emerging Markets performance included double-digit growth from China. We continue to expect China to be broadly neutral to growth for the full year. First Half 2026 Consolidated Analysis Smith+Nephew results for the first half ended 27 June 2026: Reported 27 June 2026 28 June 2025 growth $m $m % Revenue 3,097 2,961 4.6 Operating profit 448 429 4.3 Acquisition and disposal related items 21 9 Restructuring and rationalisation costs 23 8 Amortisation and impairment of acquisition intangibles 87 83 Legal and other (13) (6) Trading profit(i) 566 523 8.1 ¢ ¢ Earnings per share ('EPS') 35.6 33.5 Acquisition and disposal related items 3.6 1.8 Restructuring and rationalisation costs 2.1 0.6 Amortisation and impairment of acquisition intangibles 8.1 7.3 Legal and other (1.7) (0.3) Adjusted Earnings per share ('EPSA')(i) 47.7 42.9 11.0 (i) See Other Information on pages 30 to 36 In the first half we delivered underlying revenue growth of 2.3%, and reported revenue growth of4.6% including a 230bps tailwind from foreign exchange. There were 124 trading days, one day lessthan the equivalent period in 2025, with underlying revenue growth of 3.1% on an ADS basis. Gross profit was $2,196 million (H1 2025: $2,091 million), a 5.0% increase on a reported basis,and the gross profit margin increased 30bps to 70.9% (H1 2025: 70.6%). Trading gross profit was$2,203 million (H1 2025: $2,087 million), a 5.5% increase on a reported basis, and the gross profitmargin increased 60bps to 71.1% (H1 2025: 70.5%) as we more than offset raw materials inflationwith price increases and efficiency measures in manufacturing and procurement. Operating profitincreased 4.3% on a reported basis to $448 million (H1 2025: $429 million). The changes implemented through our 12-Point Plan have made the Group more resilient and, despite the softer than expected revenue growth, we delivered good trading profit in the first first-half, up 8.1% on a reported basis to $566 million (H1 2025: $523 million) including 90bps dilutionfrom the acquisition of Integrity Orthopaedics. The strong growth was driven by a step-up in forecastefficiency savings. While we had previously forecast a tariff headwind in the first half, the net impactof refunds received means the net impact of tariffs was broadly neutral to profit growth. We continue to make strong progress driving efficiency savings, with $130 million realised in the firsthalf. Of these, $50 million came from 12-Point Plan and zero-based budgeting (ZBB) activities, and$80 million from additional opportunities across procurement, manufacturing, sales and marketing,and business support functions. We have now achieved $330 million of cumulative 12-Point Plan and
Page 5
ZBB savings against the targets set out in August 2024 of $325 million to $375 million by 2027, withfurther savings to come through in the second half of 2026 and 2027. We expect to achieve afurther $70 million of savings in the second half from both 12-Point Plan and ZBB and otheropportunities, taking total efficiency savings for the year up from around $150 million to around $200million. This includes an additional $50 million in savings primarily coming from manufacturing,including from our ongoing footprint optimisation, as well as procurement and sales and marketing. As a result of these factors, the trading profit margin strengthened by 60bps to 18.3% (H1 2025:17.7%). A reconciliation of adjustments between operating profit and trading profit is included inOther Information on pages 30 to 36. Sports Medicine & ENT trading profit margin increased 160bps to 24.7% (H1 2025: 23.1%) driven byoperating leverage off the strong revenue growth. Advanced Wound Management trading profitmargin was down 10bps to 22.0% (H1 2025: 22.1%) reflecting changes to reimbursement in skinsubstitutes. Orthopaedics trading profit margin was up 30bps to 13.0% (H1 2025: 12.7%) as wewere able to more than offset the headwind from inventory revaluation and softer revenue growthwith manufacturing savings from network optimisation, ongoing productivity initiatives and disciplinedcost control (see Note 2 to the Interim Financial Statements for global business unit trading profit). Reported profit before tax was up 5.0% to $380 million (2025: $362 million) (see Other Informationon pages 30 to 36). Reported tax was a charge of $77 million (H1 2025: $69 million). The first half tax rate on tradingresults of 20.3% (H1 2025: 19.8%) was calculated using full year projections, applied to tradingprofits for the first half and includes non-recurring tax credits arising in this period. The applicablerate of corporate income tax has been applied to the actual non-trading items in the period on anitem-by-item basis (see Note 3 to the Interim Financial Statements and Other Information on pages30 to 36 for further details on taxation). The net interest charge within reported results was $55million (H1 2025: $54 million). Adjusted earnings per share ('EPSA') increased by 11.0% to 47.7¢ (95.4¢ per ADS) (H1 2025:42.9¢ per share). Basic earnings per share ('EPS') was up 6.2% to 35.6¢ (71.2¢ per ADS) (H12025: 33.5¢ per share), including restructuring costs, acquisition and disposal related items,amortisation and impairment of acquisition intangibles and legal and other items incurred. The Group continued to generate strong cash flow. The modest reduction in first-half trading cash flowwas driven by higher capital expenditure, primarily related to construction of our new UK Woundfactory, which is due to open next year, and IT upgrades. This year-on-year increase in investment isnot expected to recur in the second half, and we expect H2 cash generation to be stronger than in H22025. The free cash flow reflected these factors partially offset by reduced restructuring costs and,for the same reasons, we expect this to also be stronger in the second half versus H2 2025. Cashgenerated from operations was up 6.9% to $605 million (H1 2025: $568 million), trading cash flowwas down -10.2% to $437 million (H1 2025: $487 million), with trading profit to cash conversionratio of 77.3% (H1 2025: 93.0%), and free cash flow was $231 million (H1 2025: $244 million)(see Other Information on pages 30 to 36 for a reconciliation between cash generated fromoperations and trading cash flow). Net debt as of 27 June 2026 was $3,019 million (31 December 2025: $2,759 million), with accessto committed facilities of $4.7 billion (see Note 6 to the Financial Statements). The net debt toadjusted EBITDA ratio was 1.8x. Delivering our RISE strategy We are two quarters into the RISE strategy to accelerate growth and improve returns over the nextthree years, with progress across all four pillars. To REACH more patients, we are focused on driving adoption of our portfolio by expanding intoadditional indications and geographies. Highlights year to date include the first knee and shouldercases performed using the next-generation CORI XT Handheld Robotics Platform, marking animportant milestone in the clinical introduction of our latest handheld robotics technology. We alsoexpanded CATALYSTEM into Japan and initiated the European launches of our ALLEVYN COMPLETECARE Foam Dressing, which offers a unique five-layer construction with distinct mode of actioncapabilities targeted towards both wound management and pressure ulcer prevention, and of theRENASYS EDGE Negative Pressure Wound Therapy System. To INNOVATE and enhance the standard of care, we take a patient-led approach to innovation,prioritising areas with the potential to improve outcomes. We have been granted De Novo classification by the US Food & Drug Administration (FDA) for ourTESSA Spatial Surgery System. Utilising cutting-edge accelerated computing and AI technology, theTESSA (Tracking Enabled Spatial Surgery Assistant) System brings personalised planning,augmented reality, advanced imaging, navigation, and real-time tracking to help transformarthroscopic procedures. TESSA's first indication for use is femoral anterior cruciate ligamentreconstruction surgery of the knee. New product launches year to date include the FLOW FLEXTEND◊ COBLATION◊ Wand which bringsnew functionality for hard-to-reach hip, knee and shoulder anatomies, an extension to the EVOS Plating System with EVOS Pelvic, the LYNX◊ COBLATION Laryngeal Wand in ENT, and the nextgeneration LEAF Patient Monitoring System, a data-driven pressure injury prevention platformdesigned to help health care providers tackle the growing burden of hospital-acquired pressureinjuries by strengthening protocols and outcomes. We also continued to build out the evidence basesupporting our biologics portfolio, announcing new clinical data supporting adoption of ourREGENETEN and CARTIHEAL AGILI-C implants. To SCALE through strategic investment, we continue to allocate capital to targeted categories andchannels. This includes the acquisition of Integrity Orthopaedics, announced in January. TendonSeam's biomechanical approach to rotator cuff repair further expands our leading portfolio inshoulder pathology. The Group also continues to invest behind its PICO single-use NegativePressure Wound Therapy system, expanding the salesforce. Our new Advanced Wound Managementmanufacturing facility in Melton, UK, is on track to open in 2027. To EXECUTE efficiently, we are driving group-wide productivity by being disciplined around costcontrol as well as executing our Ortho 360 programme within Orthopaedics. Our Advanced WoundManagement manufacturing site in Suzhou, China, has been awarded the Shingo Prize, one of the
Page 6
world's most respected recognitions for organisational excellence reflecting more than a decade ofsustained improvement at the site. Interim Dividend Smith+Nephew has a progressive dividend policy and we expect our shareholders to benefit froman annual payout of around 35% to 40% of EPSA. The interim payment is set at 40% of the prior full year and is therefore 15.6¢ per share (31.2¢ perADS) for 2026, a 4.0% increase year-on-year (2025: 15.0¢). Share buy-back on track On 6 May 2026, Smith+Nephew announced a share buyback of $500 million to be completed withintwelve months. The buyback demonstrates our commitment to disciplined capital allocation,balancing investment in strategic growth with the return of surplus capital to shareholders, in linewith our framework. We had settled $216 million as at 3 August 2026. Outlook We expect second half revenue growth to be in the range of 5.0% to 5.5%, a step-up on the first half,driven by multiple factors, including: · In Sports Medicine, continued momentum across segments including strong growth in REGENETEN and FASTSEAL · In Advanced Wound Management, stabilisation in US skin substitutes, a return to growth in SANTYL, expansion of the European launch of ALLEVYN COMPLETE CARE, the launch of next- generation LEAF, and investment behind PICO · In Orthopaedics, improving trajectory in US Knee Implants driven by LEGION MS and the launch of the cementless version of LANDMARK, as well as a return to growth in US Hip Implants following increased CATALYSTEM set deployment · An extra trading day in the fourth quarter Consequently, we now expect to deliver full year revenue growth of around 4% (previously "around6%"). On a reported basis, the guidance equates to second half revenue growth to be in the range of5.1% to 5.6% and full year revenue growth of around 5.2% based on exchange rates prevailing on31 July 2026. Despite the revised full year revenue guidance, we continue to expect around 8% trading profitgrowth excluding acquisitions (around $1.3 billion post-acquisition of Integrity Orthopaedics),around $800 million free cash flow, and more than 10% adjusted ROIC (excluding impact ofIntegrity Orthopaedics). With the benefit of tariff refunds, we now anticipate the net year-on-year impact of tariffs to bebroadly neutral to trading profit. The headwind from skin substitutes is expected to be towards theupper end of the previously guided $20 to $40 million range. Given the updated revenue guidance, weexpect revenue leverage to be lower, offset by the $50 million step-up in forecast efficiency savings.As previously disclosed, the acquisition of Integrity Orthopaedics is expected to be marginally dilutiveto trading profit in 2026, broadly neutral in 2027 and accretive from 2028. Analyst conference call An analyst conference call to discuss Smith+Nephew's second quarter and first half results will be held today at 11.30am BST / 6.30am EDT, details of which are available on the Smith+Nephew website at https://www.smith-nephew.com/en/who- we-are/investors. Forward calendar The Q3 Trading Report will be released on 6 November 2026. Investor contacts Emily Heaven, Smith+Nephew +44 (0) 7811 919437 Craig Bijou, Smith+Nephew +1 (475) 850-8282 Media contacts Charles Reynolds, Smith+Nephew +44 (0) 1923 477314 Susan Gilchrist / Ayesha Bharmal, Brunswick +44 (0) 20 7404 5959 About Smith+Nephew Smith+Nephew is a portfolio medical technology business focused on the repair, regeneration and replacement of soft and hard tissue. We exist to restore people's bodies and their self-belief by using technology to take the limits off living. We call this purpose 'Life Unlimited'. Our 17,000 employees deliver this mission every day, making a difference to patients' lives through the excellence of our product portfolio, and the invention and application of new technologies across our three global business units of Orthopaedics, Sports Medicine & ENT and Advanced Wound Management.
Page 7
Founded in Hull, UK, in 1856, we now operate in around 100 countries, and generated annual sales of $6.2 billion in 2025. Smith+Nephew is a constituent of the FTSE100 (LSE:SN, NYSE:SNN). The terms 'Group' and 'Smith+Nephew' are used to refer to Smith & Nephew plc and its consolidated subsidiaries, unless the context requires otherwise. For more information about Smith+Nephew, please visit www.smith-nephew.com and follow us on X, LinkedIn, Instagram or Facebook. Reporting definitions Unless otherwise specified as 'reported' all revenue growth throughout this document is 'underlying' after adjusting for the effects of currency translation and including the comparative impact of acquisitions and excluding disposals. All percentages compare to the equivalent 2025 period. 'Underlying revenue growth' reconciles to reported revenue growth, the most directly comparable financial measure calculated in accordance with IFRS Accounting Standards as issued by the International Accounting Standards Board (IASB), by making two adjustments, the 'constant currency exchange effect' and the 'acquisitions and disposals effect', described below. See Other Information on pages 30 to 36 for a reconciliation of underlying revenue growth to reported revenue growth. The 'constant currency exchange effect' is a measure of the increase/decrease in revenue resulting from currency movements on non-US Dollar sales and is measured as the difference between: 1) the increase/decrease in the current year revenue translated into US Dollars at the current year average exchange rate and the prior year revenue translated at the prior year rate; and 2) the increase/decrease being measured by translating current and prior year revenues into US Dollars using the same exchange rate. The 'acquisitions and disposals effect' is the measure of the impact on revenue from newly acquired material business combinations and recent material business disposals. This is calculated by comparing the current year, constant currency actual revenue (which includes acquisitions and excludes disposals from the relevant date of completion) with prior year, constant currency actual revenue, adjusted to include the results of acquisitions and exclude disposals for the commensurate period in the prior year. These sales are separately tracked in the Group's internal reporting systems and are readily identifiable. Certain items included in 'trading results', such as trading profit, trading profit margin, tax rate on trading results, trading cash flow, trading profit to cash conversion ratio, EPSA and underlying growth are non-IFRS financial measures. The non- IFRS financial measures reported in this announcement are explained in Other Information on pages 30 to 36 and are reconciled to the most directly comparable financial measures prepared in accordance with IFRS Accounting Standards as issued by the International Accounting Standards Board (IASB). Reported results represent IFRS financial measures as shown in the Unaudited Condensed Consolidated Interim Financial Statements. Forward-looking statements This document may contain forward-looking statements that may or may not prove accurate. For example, statements regarding expected revenue growth and trading profit margins, market trends and our product pipeline are forward-looking statements. Phrases such as "aim", "plan", "intend", "anticipate", "well-placed", "believe", "estimate", "expect", "target", "consider" and similar expressions are generally intended to identify forward-looking statements. Forward-looking statements involve known and unknown risks, uncertainties and other important factors that could cause actual results to differ materially from what is expressed or implied by the statements. For Smith+Nephew, these factors include: conflicts in Europe and the Middle East, economic and financial conditions in the markets we serve, especially those affecting healthcare providers, payers and customers; price levels for established and innovative medical devices; developments in medical technology; regulatory approvals, reimbursement decisions or other government actions; product defects or recalls or other problems with quality management systems or failure to comply with related regulations; litigation relating to patent or other claims; legal and financial compliance risks and related investigative, remedial or enforcement actions; disruption to our supply chain or operations or those of our suppliers; competition for qualified personnel; strategic actions, including acquisitions and disposals, our success in performing due diligence, valuing and integrating acquired businesses; disruption that may result from transactions or other changes we make in our business plans or organisation to adapt to market
Page 8
developments; relationships with healthcare professionals; reliance on information technology and cybersecurity; disruptions due to natural disasters, weather and climate change related events; changes in customer and other stakeholder sustainability expectations; changes in taxation regulations; effects of foreign exchange volatility; and numerous other matters that affect us or our markets, including those of a political, economic, business, competitive or reputational nature. Please refer to the documents that Smith+Nephew has filed with the U.S. Securities and Exchange Commission under the U.S. Securities Exchange Act of 1934, as amended, including Smith+Nephew's most recent annual report on Form 20-F, which is available on the SEC's website at www. sec.gov, for a discussion of certain of these factors. Any forward-looking statement is based on information available to Smith+Nephew as of the date of the statement. All written or oral forward- looking statements attributable to Smith+Nephew are qualified by this caution. Smith+Nephew does not undertake any obligation to update or revise any forward-looking statement to reflect any change in circumstances or in Smith+Nephew's expectations. ◊ Trademark of Smith+Nephew. Certain marks registered in US Patent and Trademark Office. Consolidated revenue analysis for the first half 27 June 28 June Reported Underlying Acquisitions Currency 2026 2025 growth growth /disposals impact Consolidated revenue by business unit by product $m $m % % % % Sports Medicine & ENT 1,017 923 10.2 7.7 - 2.5 Sports Medicine Joint Repair 574 509 12.8 10.3 - 2.5 Arthroscopic Enabling Technologies 340 307 10.7 7.8 - 2.9 ENT (Ear, Nose and Throat) 103 107 (3.6) (5.4) - 1.8 Advanced Wound Management 867 845 2.6 (0.1) - 2.7 Advanced Wound Care 398 366 8.8 4.3 - 4.5 Advanced Wound Bioactives 263 285 (7.7) (8.1) - 0.4 Advanced Wound Devices 206 194 6.2 2.8 - 3.4 Orthopaedics 1,213 1,193 1.7 (0.1) - 1.8 Knee Implants 492 501 (1.8) (3.6) - 1.8 Hip Implants 326 313 4.3 2.3 - 2.0 Other Reconstruction 68 64 5.3 3.1 - 2.2 Trauma & Extremities 327 315 4.0 2.4 - 1.6 Total 3,097 2,961 4.6 2.3 - 2.3 Consolidated revenue by geography US 1,591 1,586 0.4 0.3 - 0.1 Other Established Markets(i) 958 897 6.7 1.4 - 5.3 Total Established Markets 2,549 2,483 2.7 0.7 - 2.0 Emerging Markets 548 478 14.8 10.6 - 4.2 Total 3,097 2,961 4.6 2.3 - 2.3 (i) Other Established Markets are Europe, Japan, Australia, Canada and New Zealand 2026 HALF YEAR CONSOLIDATED INTERIM FINANCIAL STATEMENTS Unaudited Condensed Group Income Statement for the Half Year ended 27 June 2026 27 June 28 June 2026 2025 Notes $m $m Revenue 2 3,097 2,961 Cost of goods sold (901) (870) Gross profit 2,196 2,091 Selling, general and administrative expenses (1,598) (1,519) Research and development expenses (150) (143) Operating profit 2 448 429 Interest income 10 15
Page 9
Interest expense (65) (69) Other finance costs (18) (12) Share of results of associates 5 (1) Profit before taxation 380 362 Taxation 3 (77) (69) Attributable profit for the periodA 303 293 Earnings per ordinary shareA Basic 35.6 33.5 Diluted 35.2 33.3 Unaudited Condensed Group Statement of Comprehensive Income for the Half Year ended 27 June 2026 27 June 28 June 2026 2025 $m $m Attributable profit for the periodA 303 293 Other comprehensive income Items that will not be reclassified to income statement Remeasurement of net retirement benefit obligations (1) 4 Taxation on other comprehensive income - (2) Total items that will not be reclassified to income statement (1) 2 Items that may be reclassified subsequently to income statement Cash flow hedges - forward foreign exchange contracts Gain/(loss) arising in the period 27 (47) Gain recycled to income statement in the period - (5) Foreign currency translation of foreign operations Exchange (loss)/gain on translation of foreign operations (45) 261 Exchange gain/(loss) arising on hedging instruments 25 (68) Taxation on other comprehensive income (5) 9 Total items that may be reclassified subsequently to income statement 2 150 Other comprehensive income for the period, net of taxation 1 152 Total comprehensive income for the periodA 304 445 A Attributable to the equity holders of the parent and wholly derived from continuing operations. Unaudited Condensed Group Balance Sheet as at 27 June 2026 27 June 31 December 28 June 2026 2025 2025 Notes $m $m $m ASSETS Non-current assets Property, plant and equipment 1,615 1,638 1,436 Goodwill 3,236 3,108 3,111 Intangible assets 1,109 882 962 Investments in associates 126 121 7 Investments 25 30 29 Other non-current assets 197 164 49 Retirement benefit assets 66 64 70 Deferred tax assets 252 347 401 6,626 6,354 6,065 Current assets Inventories 2,113 2,117 2,467 Trade and other receivables 1,487 1,413 1,435 Current tax receivable 33 16 49 Cash and cash equivalents 6 754 557 676 4,387 4,103 4,627 TOTAL ASSETS 11,013 10,457 10,692 EQUITY AND LIABILITIES Equity attributable to owners of the Company Share capital 175 175 175 Share premium 615 615 615 Capital redemption reserve 20 20 20 Treasury shares (733) (515) (48) Other reserves 8 (327) (329) (347) Retained earnings 5,430 5,323 5,121 Total equity 5,180 5,289 5,536 Non-current liabilities Long-term borrowings and lease liabilities 6 3,212 3,177 3,297 Retirement benefit obligations 88 84 86 Other payables 370 190 96 Provisions 72 82 94 Deferred tax liabilities 40 40 42 3,782 3,573 3,615 Current liabilities
Page 10
Bank overdrafts, borrowings, loans and lease liabilities 6 573 150 157 Trade and other payables 1,249 1,177 1,097 Provisions 68 74 58 Current tax payable 161 194 229 2,051 1,595 1,541 Total liabilities 5,833 5,168 5,156 TOTAL EQUITY AND LIABILITIES 11,013 10,457 10,692 Unaudited Condensed Group Cash Flow Statement for the Half Year ended 27 June 2026 27 June 28 June 2026 2025 $m $m Cash flows from operating activities Profit before taxation 380 362 Net interest expense 55 54 Depreciation, amortisation and impairment 300 273 Loss on disposal of property, plant and equipment and software 12 11 Share-based payments expense (equity-settled) 34 21 Share of results of associates (5) 1 Pension costs less cash paid 2 2 Increase in inventories (6) - Increase in trade and other receivables (98) (49) Decrease in trade and other payables and provisions (69) (107) Cash generated from operations 605 568 Interest received 8 14 Interest paid (63) (75) Income taxes paid (100) (111) Net cash inflow from operating activities 450 396 Cash flows from investing activities Acquisitions, net of cash acquired (221) (8) Capital expenditure (190) (139) Proceeds from disposal of property, plant and equipment - 12 Net cash used in investing activities (411) (135) Cash flows from financing activities Purchase of own shares (116) - Proceeds from own shares 3 1 Payment of capital element of lease liabilities (29) (25) Proceeds from borrowings due within one year 23 27 Settlement of borrowings due within one year (87) (13) Proceeds from borrowings due after one year 578 - Settlement of currency swaps (10) (5) Equity dividends paid (205) (202) Net cash inflow/(used) in financing activities 157 (217) Net increase in cash and cash equivalents 196 44 Cash and cash equivalents at beginning of the period 553 617 Exchange adjustments 1 12 Cash and cash equivalents at end of the periodB 750 673 B Cash and cash equivalents at the end of the period is net of overdrafts of $4m (28 June 2025: $3m). Unaudited Condensed Group Statement of Changes in Equity for the Half Year ended 27 June 2026 Capital Share Share redemption Treasury Other Retained Total capital premium reserve shares reservesC earningsD equity $m $m $m $m $m $m $m At 1 January 2026 175 615 20 (515) (329) 5,323 5,289 Attributable profit for the periodA - - - - - 303 303 Other comprehensive incomeA - - - - 2 (1) 1 Total comprehensive income - - - - 2 302 304 Equity dividends declared and paid - - - - - (205) (205) Share-based payments recognised - - - - - 34 34 Taxation on share-based payments - - - - - 5 5 Purchase of own sharesC - - - (250) - - (250) Cost of shares transferred to beneficiaries - - - 32 - (29) 3 At 27 June 2026 175 615 20 (733) (327) 5,430 5,180
Page 11
Capital Share Share redemption Treasury Other Retained Total capital premium reserve shares reservesC earningsD equity $m $m $m $m $m $m $m At 1 January 2025 175 615 20 (66) (497) 5,018 5,265 Attributable profit for the periodA - - - - - 293 293 Other comprehensive incomeA - - - - 150 2 152 Total comprehensive income - - - - 150 295 445 Equity dividends declared and paid - - - - - (202) (202) Share-based payments recognised - - - - - 21 21 Taxation on share-based payments - - - - - 6 6 Cost of shares transferred to beneficiaries - - - 18 - (17) 1 At 28 June 2025 175 615 20 (48) (347) 5,121 5,536 A Attributable to the equity holders of the parent and wholly derived from continuing operations. C Refer to Note 8 for further information. D Within retained earnings is a non-distributable capital reserve of $2,266m (1 January 2026: $2,266m, 28 June 2025: $2,266m) which arose as a result of the Group's reorganisation in 2008. Notes to the Condensed Consolidated Interim Financial Statements 1. Basis of preparation and accounting policies Smith & Nephew plc (the 'Company') is a public limited company incorporated in England and Wales. In these condensed consolidated interim financial statements ('Interim Financial Statements'), 'Group' means the Company and all its subsidiaries. These Interim Financial Statements have been prepared in accordance with IAS 34 Interim Financial Reporting as adopted for use in the UK. As required by the Disclosure Guidance and Transparency Rules of the Financial Conduct Authority, these Interim Financial Statements have been prepared applying the accounting policies and presentation that were applied in the preparation of the Company's annual accounts for the year ended 31 December 2025 which were prepared in accordance with UK-adopted International Accounting Standards. The Group has also prepared its accounts in accordance with IFRS Accounting Standards as issued by the International Accounting Standards Board (IASB) effective as at 31 December 2025. IFRS Accounting Standards as adopted in the UK differs in certain respects from IFRS Accounting Standards as issued by the IASB. However, the differences have no impact for the periods presented. The uncertainties as to the future impact on the financial performance and cash flows of the Group as a result of the current economic environment have been considered as part of the Group's adoption of the going concern basis for its Interim Financial Statements for the period ended 27 June 2026, in which context the Directors reviewed cash flow forecasts prepared for a period of at least 12 months from the date of approval of these Interim Financial Statements. Having carefully reviewed those forecasts, the Directors concluded that it was appropriate to adopt the going concern basis of accounting in preparing these Interim Financial Statements for the reasons set out below. The Group has access to $750m of cash and cash equivalents (net of overdrafts) at 27 June 2026.The Group's net debt at 27 June 2026 was $3,019m (see Note 6) with committed facilities of $4.7bn. No debt is due for repayment in the second half of 2026. A $350m US
Page 12
Corporate Bond and $140m of private placement debt is due for repayment in the first half of 2027. $550m of private placement debt is subject to financial covenants. The principal covenant on the private placement debt is a leverage ratio of <3.5x which is measured on a rolling 12-month basis at half year and year end. There are no financial covenants in any of the Group's other facilities. The Directors have considered various scenarios in assessing the impact of the economic environment on future financial performance and cash flows, including the impact of a significant global economic downturn, leading to lower healthcare spending across both public and private systems. Throughout these scenarios, which include a severe, but plausible outcome, the Group continues to have headroom on its borrowing facilities and financial covenants. The Directors have a reasonable expectation that the Company and the Group are well placed to manage their business risks, have sufficient funds to continue to meet their liabilities as they fall due and to continue in operational existence for a period of at least 12 months from the date of the approval of these financial statements. The financial statements have therefore been prepared on a going concern basis. Accordingly, the Directors continue to adopt the going concern basis (in accordance with the guidance 'Guidance on the Going Concern Basis of Accounting and Related Reporting (including Solvency and Liquidity Risks)' issued by the FRC) in preparing these financial statements. New accounting standards effective 2026 A number of new amendments to standards are effective from 1 January 2026 but they do not have a material effect on the Group's financial statements. Accounting standards issued but not yet effective A number of new standards and amendments to standards are effective for annual periods beginning after 1 January 2027 and earlier application is permitted; however, the Group has not early adopted them in preparing these Interim Financial Statements. IFRS 18 Presentation and Disclosure in Financial Statements was issued by the IASB in April 2024. The standard is effective for annual reporting periods beginning on or after 1 January 2027, and also applies to comparative information. IFRS 18 will replace IAS 1 Presentation of Financial Statements and will have a pervasive impact on several aspects of financial statements presentation and disclosure, particularly in the Group income statement and disclosure requirements for management-defined performance measures (MPMs) within the financial statements. The Group has commenced an assessment of the standard's full impact. Based on the preliminary analysis, the Group anticipates that the standard will have the following potential impacts: - The classification of items of income and expense into categories defined in IFRS 18 will impact the presentation of the Group income statement. Whilst the standard does not impact recognition or measurement, changes in classification will impact the reported amounts for line items in the income statement. A new subtotal 'Profit before financing and income tax' will be included to separately present the impact of investing and financing activities. Share of results of associates will be classified in the investing category, interest income and expense in the financing category and other finance costs
Page 13
will be classified in the operating, investing or financing category depending on the nature of the income or expense. - The Group is reassessing its aggregation and disaggregation principles to ensure they comply with the enhanced guidance in IFRS 18, which aims to provide more detailed and useful information to users of the financial statements. - Mandatory new disclosures in relation to MPMs will be required within the financial statements. - Consequential presentational changes to statement of cash flows will be required and operating profit will be the new starting point for reconciling cash flows from operating activities. The Group will apply IFRS 18 from its mandatory effective date of 1 January 2027. Comparative information for the year ending 31 December 2026 and period ending 27 June 2026 will be restated in the Interim Financial Statements for the period ending 26 June 2027 in accordance with IFRS 18. Critical judgements and estimates The Group prepares its consolidated financial statements in accordance with IFRS Accounting Standards as issued by the IASB and IFRS adopted in the UK, the application of which often requires judgements and estimates to be made by management when formulating the Group's financial position and results. Under IFRS Accounting Standards, the Directors are required to adopt those accounting policies most appropriate to the Group's circumstances for the purpose of presenting fairly the Group's financial position, financial performance and cash flows. Consistent with the Group's consolidated financial statements for the year ended 31 December 2025, there are no critical accounting judgements and no key sources of estimation uncertainty that have a significant risk of resulting in a material adjustment to the carrying amounts of assets and liabilities within the next 12 months. Climate change considerations The impact of climate change has been considered as part of the assessment of estimates and judgements in preparing the Interim Financial Statements. The climate change scenario analyses undertaken this year in line with TCFD recommendations did not identify any material financial impact. The following considerations were made in respect of the interim financial statements: a. The impact of climate change on the going concern assessment; b. The impact of climate change on the cash flow forecasts used in the impairment assessments of non-current assets including goodwill; and c. The impact of climate change on the carrying value and useful economic lives of property, plant and equipment. While there is currently no material medium term impact expected, the Group closely monitors climate-related risks given the changing nature of these risks and management consider the impact of climate change as part of the decision making process and continue to assess the impact on judgements and estimates, and on preparation of the consolidated financial statements. 2. Business segment information The Group's operating structure is organised around four global business units (Sports Medicine, ENT, Advanced Wound Management and Orthopaedics) and the chief operating decision maker monitors performance, makes operating decisions and allocates resources on a global business unit basis. Business unit presidents have responsibility for upstream marketing, driving product portfolio and technology acquisition decisions, full commercial
Page 14
responsibility and for the implementation of their business unit strategy globally. Accordingly, the Group consists of four operating segments. The Group has concluded that Sports Medicine and ENT meet the aggregation criteria and therefore, these operating segments have been aggregated into a single operating segment. In applying the aggregation criteria prescribed by IFRS 8 Operating Segments, management made certain judgements pertaining to the economic indicators relating to these operating segments including those relating to the similarities in the expected long-term market growth rates, the geographic and operational risks and the competitive landscape that these segments operate in. Accordingly, as described in Note 2 to the most recent annual report, the Group has concluded that there are three operating segments which are also reportable segments. Segment revenue reconciles to statutory revenue from continuing operations as follows: 27 June 28 June 2026 2025 $m $m Reportable segment revenue Sports Medicine & ENT 1,017 923 Advanced Wound Management 867 845 Orthopaedics 1,213 1,193 Revenue from external customers 3,097 2,961 2a. Disaggregation of revenue The following table shows the disaggregation of Group revenue by product by business unit: 27 June 28 June Revenue by product from continuing operations 2026 2025 $m $m Sports Medicine Joint Repair 574 509 Arthroscopic Enabling Technologies 340 307 ENT (Ear, Nose and Throat) 103 107 Sports Medicine & ENT 1,017 923 Advanced Wound Care 398 366 Advanced Wound Bioactives 263 285 Advanced Wound Devices 206 194 Advanced Wound Management 867 845 Knee Implants 492 501 Hip Implants 326 313 Other Reconstruction 68 64 Trauma & Extremities 327 315 Orthopaedics 1,213 1,193 Total 3,097 2,961 The following table shows the disaggregation of Group revenue by geographic market and product category. The disaggregation of revenue into the two product categories below reflects that in general the products in the Advanced Wound Management business unit are sold to wholesalers and intermediaries, while products in the other business units are sold directly to hospitals, ambulatory surgery centers and distributors. The further disaggregation of revenue by Established Markets and Emerging Markets reflects that in general our products are sold through distributors and intermediaries in the Emerging Markets while in the Established Markets, with the exception of the Advanced Wound Care and Bioactives, products are in general sold direct to hospitals and ambulatory surgery centers. The disaggregation by Established Markets and Emerging Markets also reflects their differing economic factors including volatility in growth and outlook. 27 June 2026 28 June 2026 Established MarketsE Emerging Markets Total Established MarketsE Emerging Markets Total $m $m $m $m $m $m Orthopaedics, Sports Medicine & ENT 1,810 420 2,230 1,752 364 2,116 Advanced Wound Management 739 128 867 731 114 845 Total 2,549 548 3,097 2,483 478 2,961 E Established Markets comprises US, Australia, Canada, Europe, Japan and New Zealand.
Page 15
Sales are attributed to the country of destination. US revenue for the half year was $1,591m (H1 2025: $1,586m) and UK revenue for the half year was $115m (H1 2025: $114m). No individual customer comprises more than 10% of the Group's external sales. 2b. Trading profit by business segment The segment profit measure presented to the ExCo is the segment trading profit. The Group has identified the following items as those to be excluded from operating profit when arriving at segment trading profit: corporate costs; acquisition and disposal-related items; significant restructuring programmes; amortisation and impairment of acquisition intangibles; gains and losses arising from legal disputes; and other significant items. Segment trading profit is reconciled to the statutory measure below: 27 June 28 June 2026 2025 $m $m Segment profit Sports Medicine & ENT 251 213 Advanced Wound Management 191 187 Orthopaedics 158 151 Segment trading profit 600 551 Corporate costs1 (34) (28) Acquisition and disposal related items (21) (9) Restructuring and rationalisation expenses (23) (8) Amortisation and impairment of acquisition intangibles (87) (83) Legal and other 13 6 Operating profit 448 429 Interest income 10 15 Interest expense (65) (69) Other finance costs (18) (12) Share of results of associates 5 (1) Profit before taxation 380 362 1 Corporate costs include centralised infrastructure costs such as compliance and group functions. Depreciation and amortisation included in segment profit is presented below: 27 June 28 June 2026 2025 $m $m Depreciation and amortisation Sports Medicine & ENT 55 51 Advanced Wound Management 37 34 Orthopaedics 115 112 Acquisition and disposal related items For the half year ended 27 June 2026, the charge included integration costs relating to the acquisition of Integrity Orthopaedics and prior year acquisitions. For the half year ended 28 June 2025, the charge included costs of integration for prior year acquisitions. Restructuring and rationalisation costs For the half year ended 27 June 2026, these costs primarily relate to the efficiency and productivity elements of the 12-Point Plan and the Operations and Commercial Excellence programme. These costs primarily consist of severance, integration and dual running costs. For the half year ended 28 June 2025, these costs primarily relate to the efficiency and productivity elements of the 12-Point Plan and the Operations and Commercial Excellence programme. These costs primarily consist of severance, integration and dual running costs, partially offset by gains on disposal of property, plant and equipment.
Page 16
Amortisation and impairment of acquisition intangibles For both the half years ended 27 June 2026 and 28 June 2025, charges relate to the amortisation and impairment of intangible assets acquired in material business combinations. Legal and other For the half year ended 27 June 2026, charges relate to legal expenses for ongoing metal- on-metal hip claims. These expenses were offset by a release of $21m in the provision that reflects the decrease in the present value of the estimated costs to resolve all other known and anticipated metal-on-metal hip claims. For the half year ended 28 June 2025, charges relate to legal expenses for ongoing metal- on-metal hip claims. These expenses were offset by a release of $11m in the provision that reflects the decrease in the present value of the estimated costs to resolve all other known and anticipated metal-on-metal hip claims. 3. Taxation Tax rate Our reported tax for the period ended 27 June 2026 was a charge of $77m, with an effective tax rate of 20.3% (H1 2025: $69m, effective tax rate of 19.1%). OECD BEPS 2.0 - Pillar Two The Group estimates a Pillar Two current tax charge for the year ending 31 December 2026 of $19m (2025: $8m). The Group is adopting the IAS12 mandatory temporary exception from the recognition and disclosure of deferred taxes arising from the jurisdictional implementation of the Pillar Two model rules. 4. Dividends The 2025 final dividend totaling $205m was paid on 27 May 2026. The 2026 interim dividend of 15.6 US cents per ordinary share was approved by the Board on 29 July 2026. This dividend is payable on 6 November 2026 to shareholders whose names appear on the register at the close of business on 2 October 2026. The sterling equivalent per ordinary share will be set following the record date. Shareholders may elect to receive their dividend in either Sterling or US Dollars and the last day for election will be 16 October 2026. Shareholders may participate in the dividend re-investment plan and elections must be made by 16 October 2026. 5. Acquisitions Half year ended 27 June 2026 On 21 January 2026, the Group completed the acquisition of 100% of the share capital of Integrity Orthopaedics Inc. (Integrity), a US-based early-stage commercial developer of Tendon Seam™, an innovative rotator cuff repair (RCR) system designed to significantly reduce re tear rates and improve patient outcomes. The acquisition represents a meaningful step in delivering Smith+Nephew's RISE strategy to accelerate growth through strategic investment and portfolio leadership, and will be an important building block in our ambition to become the global leader in Sports Medicine. The fair value of the consideration amounted to $390m. This comprises contingent consideration of $165m, representing the discounted value of future payments contingent
Page 17
upon the achievement of specified financial performance milestones in the next 3 years, and initial cash consideration of $225m adjusted for cash acquired and other liabilities assumed. The purchase price allocation remains provisional as of the date on which the financial statements were approved by the Board, principally because of the ongoing assessment of historic tax losses recognised by Integrity prior to the acquisition. The provisional fair values of assets acquired, and liabilities assumed are set out below: Integrity $m Intangible assets - technology-related 321 Inventory 1 Cash 5 Other Assets 2 Other liabilities (7) Trade and other payables (1) Net deferred tax liability (71) Net assets 250 Goodwill 140 Consideration 390 The goodwill represents the control premium, acquired workforce and the synergies expected to arise from integrating Integrity into the Group's existing operations. The technology-related intangible assets were valued using an income-based valuation approach, with key inputs including forecast revenue, profitability and discount rates over the expected life of the technology. The contribution of Integrity Orthopaedics to the Group's revenue and profit for the period following acquisition is not material relative to the Group's overall performance. The cash outflow from acquisitions in H1 2026 was $221m comprising consideration of $220m net of cash acquired of $5m relating to acquisitions in the current period, and payments of deferred and contingent consideration of $1m for acquisitions completed in prior periods. The carrying value of goodwill increased from $3,108m at 31 December 2025 to $3,236m at 27 June 2026. The Integrity Orthopaedics acquisition during the period increased goodwill by $140m, this was partially offset by foreign exchange movements of $12m. Year ended 31 December 2025 No acquisitions were completed in 2025. The cash outflow from acquisitions in H1 2025 comprises payments of deferred and contingent consideration of $8m for acquisitions completed in prior periods. 6. Net debt Net debt as at 27 June 2026 is outlined below. The repayment of lease liabilities is included in cash flows from financing activities in the cash flow statement. 27 June 31 December 28 June 2026 2025 2025 $m $m $m Bank overdrafts, borrowings and loans - current 508 83 18 Corporate bond1 2,670 2,478 2,603 Private placement notes 410 550 625 Borrowings 3,588 3,111 3,246 Cash and cash equivalents2 (754) (557) (676) Asset balance on derivatives - interest rate swaps (12) (11) (31) Net debt excluding lease liabilities 2,822 2,543 2,539 Non-current lease liabilities 132 149 144 Current lease liabilities 65 67 64 Net debt 3,019 2,759 2,747
Page 18
1 Corporate bond includes fair value adjustment relating to interest swaps. 2 In H1 2026, cash and cash equivalents include cash at bank of $504m (31 December 2025: $457m, 28 June 2025: $476m) and cash equivalents of $250m (31 December 2025: $100m, 28 June 2025: $200m). No debt is due for repayment in the second half of 2026. A $350m US Corporate Bond and $140m of private placement debt is due for repayment in the first half of 2027. In June 2026, the Group issued a corporate bond of €500m (before expenses and underwriting discounts) bearing an interest rate of 4.25% repayable in 2038. Part of the Group's net investment in its Euro subsidiaries is hedged by the two EUR Corporate Bonds of €500m each issued in 2022 and 2026 which mitigates the foreign currency risk arising from the subsidiaries' net assets. The €500m Bond issued in 2026 has been designated as a hedging instrument for the changes in the value of the net investment that is attributable to changes in the EUR/USD spot rate. The Group may, at any time and from time to time, seek to retire, repay or repurchase its outstanding debt, including through cash tender offers, open-market repurchases, privately negotiated transactions or otherwise. Any such transactions, if undertaken, would be on terms and at prices determined by the Group and would depend on prevailing market conditions, liquidity requirements, contractual restrictions and other relevant factors. The Company is subject to financial covenants under its private placement agreements. The principal covenant on the private placement debt is a leverage ratio of <3.5 which is measured on a rolling 12-month basis at half year and year end using net debt excluding lease liabilities as set out below. The financial covenants are tested at the end of each half year for the 12 months ending on the last day of the testing period. As of 27 June 2026, the Company was in compliance with these covenants. The facilities are also subject to customary events of default, none of which are currently anticipated to occur. As the measure included in the financial covenants represents net debt excluding lease liabilities, the Group also presents the net debt position to provide a complete and comprehensive view of its financial position. 7a. Financial instruments The following table shows the carrying amounts and fair values of financial assets and financial liabilities, including their levels in the fair value hierarchy. Carrying amount Fair value 27 June 31 December 28 June 27 June 31 December 28 June 2026 2025 2025 2026 2025 2025 Fair value $m $m $m $m $m $m level Financial assets measured at fair value
Page 19
Forward foreign exchange contracts 54 33 2 54 33 2 Level 2 Investments 25 30 29 25 30 29 Level 1 & 3 Investments relating to deferred compensation arrangements 120 106 - 120 106 - Level 1 Interest rate swaps 15 11 31 15 11 31 Level 2 Currency swaps 1 2 - 1 2 - Level 2 215 182 62 215 182 62 Financial assets not measured at fair value Trade and other receivables 1,354 1,278 1,296 Cash and cash equivalents 754 557 676 2,108 1,835 1,972 Total financial assets 2,323 2,017 2,034 Financial liabilities measured at fair value Acquisition consideration - contingent (286) (107) (89) (286) (107) (89) Level 3 Forward foreign exchange contracts (8) (15) (36) (8) (15) (36) Level 2 Interest rate swaps (3) - - (3) - - Level 2 Currency swaps (1) (2) - (1) (2) - Level 2 (298) (124) (125) (298) (124) (125) Financial liabilities not measured at fair value Acquisition consideration - deferred - - (9) Bank overdrafts and loans (19) (8) (17) Corporate bond not in a hedge relationship (1,395) (1,394) (1,493) Corporate bond in a hedge relationship (1,624) (1,084) (1,110) Private placement debt not in a hedge relationship (550) (625) (625) Trade and other payables (1,208) (1,243) (1,060) (4,796) (4,354) (4,314) Total financial liabilities (5,094) (4,478) (4,439) The following table shows the book value and market value of corporate bonds and private placement debt. 27 June 2026 31 December 2025 28 June 2025 Book Market Book Market Book Market value value value value value value $ million $ million $ million $ million $ million $ million 2030 USD corporate bond 897 802 897 810 996 875 2034 USD corporate bond 635 659 641 672 648 659 2027 USD corporate bond 349 351 349 354 348 354 2029 EUR corporate bond 571 594 591 617 611 623 2038 EUR corporate bond 567 580 - - - - Private placement debt 550 516 625 594 625 589 In January 2026, the Group transferred an investment with a fair value of $20m from Level 3 to Level 1 following the expiration of a value protection arrangement, after which the fair value was determined by reference to quoted market prices. There were no transfers between Levels 1 and 2 during the period. There were no transfers between Levels 1, 2 and 3 during the year ended 31 December 2025. For cash and cash equivalents, short-term loans and receivables, overdrafts and other short-term liabilities which have a maturity of less than three months, the book values approximate the fair values because of their short-term nature. Long-term borrowings are measured in the balance sheet at amortised cost. The corporate bonds issued in October 2020, October 2022, March 2024 and June 2026 are publicly listed and a market price is available. The Group's other long-term borrowings are not quoted publicly, their fair values are estimated by discounting future contractual cash flows to net present values at the current market interest rates available to the Group for similar financial instruments as at the year end. The fair value of the private placement notes is determined using a discounted cash flow model based on prevailing market rates. Fair value of investments relating to deferred compensation arrangements is determined using unadjusted quoted market prices, and accordingly these investments are classified as
Page 20
Level 1 within the fair value hierarchy. The fair value of forward exchange contracts is calculated by reference to quoted market forward exchange rates for contracts with similar maturity profiles. The fair value of interest rate swaps is determined by reference to quoted market interest rates. The fair value of currency swaps is determined by reference to quoted market spot rates. As a result, foreign forward exchange contracts, interest rate swaps and currency swaps are classified as Level 2 within the fair value hierarchy. The fair value of contingent acquisition consideration is estimated using a discounted cash flow model. The valuation model considers the present value of expected payment, discounted using a risk-adjusted discount rate. The expected payment is determined by considering the possible scenarios, which relate to the achievement of established milestones and targets, the amount to be paid under each scenario and the probability of each scenario. As a result, contingent acquisition consideration is classified as Level 3 within the fair value hierarchy. Fair value of quoted investments is determined using unadjusted quoted market prices, and accordingly these investments are classified as Level 1 within the fair value hierarchy. The fair value of unquoted investments is based upon third party pricing models for share issues. As a result, unquoted investments are considered Level 3 in the fair value hierarchy. The movements in the half year ended 27 June 2026 and the year ended 31 December 2025 for financial instruments measured using Level 3 valuation methods are presented below: 27 June 31 December 2026 2025 $m $m Investments At 1 January 30 9 Transferred to Level 1 (20) - Additions 2 2 Transferred from receivables - 18 Fair value remeasurement - 1 12 30 Contingent acquisition consideration liability At 1 January (107) (84) Arising on acquisitions (165) - Payments 1 6 Remeasurements (15) (29) (286) (107) 7b. Retirement benefit obligations The discount rates applied to the defined benefit pension liabilities of the UK, Germany and Switzerland pension plans are determined based on the yield on bonds that have a credit rating of AA denominated in the currency in which the benefits are expected to be paid with a maturity profile approximately the same as the obligations. Since 31 December 2025, the discount rate for UK has increased by 50 basis points to 6.0%, the discount rate for Germany has increased by 20 basis points to 4.6% and the discount rate for Switzerland has decreased by 5 basis points to 1.15%. A remeasurement loss of $1m was recognised in Other Comprehensive Income (OCI) during the first half of 2026, reflecting actuarial movements in the present value of the pension obligations in the UK, Germany and Switzerland. 8. Equity Other reserves comprises gains and losses on cash flow hedges, foreign exchange differences on translation of foreign operations and net changes on fair value of trade investments. Cumulative fair value loss on trade investments within other reserves at 27 June 2026 was $11m (1 January 2026: $11m, 28 June 2025: $11m). The movement in the cash flow hedge reserve and foreign currency translation reserve is as follows: 27 June 28 June 2026 2025
Page 21
Foreign currency translation reserve $m $m At 1 January (341) (520) Exchange (loss)/gain on translation of foreign operations (45) 261 Exchange gain/(loss) arising on hedging instruments 25 (68) (361) (327) 27 June 28 June 2026 2025 Cash flow hedge reserve $m $m At 1 January 18 34 Gain/(loss) arising in the period 27 (47) Gain recycled to income statement in the period - (5) Taxation - 9 45 (9) On 6 May 2026, the Group announced a $500m share buyback programme in order to return capital to shareholders. The Group purchased 9,076,588 shares under the programme for a total cost of $137m and has an obligation to purchase additional shares amounting to $113m at 27 June 2026. The total cost of $250m has been deducted from equity. Of this amount, $116m was settled during the period ended 27 June 2026. Transaction costs relating to the shares purchased were immaterial. This new buyback follows the $500m buyback completed in 2025. 9. Exchange rates The exchange rates used for the translation of currencies into US Dollars that have the most significant impact on the Group results were: 27 June 31 December 28 June 2026 2025 2025 Average rates Sterling 1.35 1.32 1.30 Euro 1.17 1.13 1.09 Swiss Franc 1.27 1.20 1.16 Japanese Yen 0.0063 0.0067 0.0067 Period end rates Sterling 1.32 1.35 1.37 Euro 1.14 1.17 1.17 Swiss Franc 1.24 1.26 1.26 Japanese Yen 0.0062 0.0064 0.0069 10. Contingencies The Company and its subsidiaries are party to various legal proceedings, some of which include claims for substantial damages. The outcome of these proceedings cannot readily be foreseen, but except as described herein management believes none of them is likely to result in a material adverse effect on the financial position of the Group. The Group provides for outcomes that are deemed to be probable and can be reliably estimated. There is no assurance that losses will not exceed provisions or will not have a significant impact on the Group's results of operations in the period in which they are realized. 11. Subsequent events There have been no events between the balance sheet date, and the date on which the financial statements were approved by the Board, which would require adjustment to the financial statements or any additional disclosures. 12. Principal risks and uncertainties The principal risks and uncertainties that the Group is exposed to are consistent with those as at 31 December 2025. The principal risks and uncertainties continue to be: legal and compliance; quality and regulatory; political and economic; financial markets; pricing and reimbursement; cybersecurity; global supply chain; mergers and acquisitions; new product innovation, design and development including intellectual property; strategy and commercial execution; and talent management. Further detail on these risks can be found in the 2025 Annual Report of the Group on pages 83-94.
Page 22
Directors' Responsibilities Statement The Directors confirm that to the best of their knowledge: · this set of condensed consolidated Interim Financial Statements has been prepared in accordance with IAS 34 Interim Financial Statements as adopted for use in the UK and IAS 34 Interim Financial Statements as issued by the International Accounting Standards Board; and · that the interim management report herein includes a fair review of the information required by: a. DTR 4.2.7R of the Disclosure and Transparency Rules, being an indication of important events that have occurred during the first six months of the financial year and their impact on the condensed set of financial statements; and a description of the principal risks and uncertainties for the remaining six months of the year; and b. DTR 4.2.8R of the Disclosure and Transparency Rules, being related party transactions that have taken place in the first six months of the current financial year and that have materially affected the financial position or performance of the enterprise during that period, and any changes in the related party transactions described in the last annual report that could do so. The Directors of Smith & Nephew plc are listed in the Smith & Nephew plc Annual Report for 31 December 2025. A list of current Directors is maintained on the Smith & Nephew plc website: www.smith-nephew.com. The Directors are responsible for the maintenance and integrity of the Group's website. Legislation in the United Kingdom governing the preparation and dissemination of Financial Statements may differ from legislation in other jurisdictions. By order of the Board: Deepak Nath Chief Executive Officer 3 August 2026 John Rogers Chief Financial Officer 3 August 2026 INDEPENDENT REVIEW REPORT TO SMITH & NEPHEW PLC Conclusion We have been engaged by the company to review the condensed set of financial statements in the interim financial report for the half-year ended 27 June 2026 which comprises the Condensed Group Income Statement, the Condensed Group Statement of Comprehensive Income, the Condensed Group Balance Sheet, the Condensed Group Cash Flow Statement, the Group Statement of Changes in Equity and related notes 1 to 12.
Page 23
Based on our review, nothing has come to our attention that causes us to believe that the condensed set of financial statements in the interim financial report for the half-year ended 27 June 2026 is not prepared, in all material respects, in accordance with United Kingdom adopted International Accounting Standard 34 and the Disclosure Guidance and Transparency Rules ("the DTR") of the United Kingdom's Financial Conduct Authority ("the UK FCA"). Basis for Conclusion We conducted our review in accordance with International Standard on Review Engagements (UK) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Financial Reporting Council for use in the United Kingdom (ISRE (UK) 2410). A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with International Standards on Auditing (UK) and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion. As disclosed in note 1, the annual financial statements of the group are prepared in accordance with United Kingdom adopted international accounting standards. The condensed set of financial statements included in this interim financial report has been prepared in accordance with United Kingdom adopted International Accounting Standard 34, "Interim Financial Reporting". Conclusion Relating to Going Concern Based on our review procedures, which are less extensive than those performed in an audit as described in the Basis for Conclusion section of this report, nothing has come to our attention to suggest that the directors have inappropriately adopted the going concern basis of accounting or that the directors have identified material uncertainties relating to going concern that are not appropriately disclosed. This Conclusion is based on the review procedures performed in accordance with ISRE (UK) 2410; however future events or conditions may cause the entity to cease to continue as a going concern. Responsibilities of the directors The directors are responsible for preparing the interim financial report in accordance with the DTR of the UK FCA. In preparing the interim financial report, the directors are responsible for assessing the group's ability to continue as a going concern, disclosing as applicable, matters related to going concern and using the going concern basis of accounting unless the directors either intend to liquidate the company or to cease operations, or have no realistic alternative but to do so. Auditor's Responsibilities for the review of the financial information In reviewing the interim financial report, we are responsible for expressing to the company a conclusion on the condensed set of financial statements in the interim financial report. Our Conclusion, including our Conclusion Relating to Going Concern, are based on procedures that are less extensive than audit procedures, as described in the Basis for Conclusion paragraph of this report. Use of our report
Page 24
This report is made solely to the company in accordance with ISRE (UK) 2410. Our work has been undertaken so that we might state to the company those matters we are required to state to it in an independent review report and for no other purpose. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than the company, for our review work, for this report, or for the conclusions we have formed. Deloitte LLP Statutory Auditor London, United Kingdom 3 August 2026 Other information These Interim Financial Statements include financial measures that are not prepared in accordance with IFRS Accounting Standards as issued by the International Accounting Standards Board (IASB). This additional information presented is not uniformly defined by all companies including those in the Group's industry. Accordingly, it may not be comparable with similarly titled measures and disclosures by other companies. Additionally, certain information presented is derived from amounts calculated in accordance with IFRS Accounting Standards but is not itself a measure defined under IFRS Accounting Standards. Such measures should not be viewed in isolation or as an alternative to the equivalent GAAP measure. The non-IFRS measures discussed in this document are set out below. Performance measures Non-IFRS measure Purpose Definition Closest equivalent IFRS measure Reconciled on Underlying revenue growth Underlying revenue growth is used to compare revenue in a given year to the previous year on a like-for-like basis. This measure is used by both management and the investor community. Underlying revenue growth reconciles to reported revenue growth, the most directly comparable financial measure calculated in accordance with IFRS Accounting Standards, by making two adjustments, the 'constant currency exchange effect' and the 'acquisitions and disposals effect'. The 'constant currency exchange effect' is a measure of the increase/decrease in revenue resulting from currency movements on non-US Dollar sales and is measured as the difference between: 1) the increase/decrease in the current year revenue translated into US Dollars at the current year average exchange rate and the prior year revenue translated at the prior year rate; and 2) the increase/decrease being measured by translating current and prior year revenues into US Dollars using the same exchange rate. The 'acquisitions and disposals effect' is the measure of the impact on revenue from newly acquired material business combinations and recent material business disposals. This is calculated by comparing the current year, constant currency actual revenue (which includes acquisitions and excludes disposals from the relevant date of completion) with prior year, constant currency actual revenue, adjusted to include the results of acquisitions and exclude disposals for the commensurate period in the prior year. These sales are separately tracked in the Group's internal reporting systems and are readily identifiable. Revenue growth 34 Average daily sales Average daily sales is used to assess underlying revenue growth by removing the effect of different trading days between periods. This is a key metric used by management to assess the performance of the Group. Average daily sales is calculated by dividing revenue at a constant exchange rate by the number of trading days in a given period. Trading days refer to the days on which the Group generates its revenue. Revenue n/a
Page 25
Performance measures (continued) Trading profit Trading profit is used in conjunction with operating profit to assess the performance and profitability of the Group. It is a key internal and external metric used by the investor community to assess our performance. It is our segment performance measure in accordance with IFRS 8 Operating Segments. Trading profit is operating profit excluding the impact of acquisition and disposal related items arising in connection with business combinations, including amortisation of acquisition intangible assets, impairments and integration costs; restructuring events; and gains and losses resulting from legal disputes and uninsured losses. In addition to these items, gains and losses that materially impact the Group's profitability on a short-term or one- off basis are excluded. Operating profit 34 Trading profit margin This measure is used to assess the performance and profitability of the Group. It is a key external metric used by the investor community to assess our performance. Trading profit margin is trading profit divided by revenue. Operating profit margin 34 Trading profit before tax Trading profit before tax is used in conjunction with profit before tax to assess performance and profitability of the Group. This measure is intended to enable the users to assess the performance of the Group by excluding items that impact the short-term profitability of the Group. Trading profit before tax is profit before tax excluding impact of acquisition and disposal related items arising in connection with business combinations, including amortisation of acquisition intangible assets, impairments and integration costs; restructuring events; and gains and losses resulting from legal disputes and uninsured losses. In addition to these items, gains and losses that materially impact the Group's profitability on a short-term or one- off basis are excluded. Profit before tax 34 Trading taxation Trading taxation is used in conjunction with taxation to assess taxation that corresponds to trading profit before tax. This metric is used by both management and the investor community. Trading taxation is taxation excluding the impact of acquisition and disposal related items arising in connection with business combinations, including amortisation of acquisition intangible assets, impairments and integration costs; restructuring events; and gains and losses resulting from legal disputes and uninsured losses. In addition to these items, gains and losses that materially impact the Group's profitability on a short-term or one- off basis are excluded. Taxation 34 Trading attributable profit This metric is used in the calculation of adjusted basic earnings per share. Trading attributable profit is attributable profit excluding the impact of acquisition and disposal related items arising in connection with business combinations, including amortisation of acquisition intangible assets, impairments and integration costs; restructuring events; and gains and losses resulting from legal disputes and uninsured losses. In addition to these items, gains and losses that materially impact the Group's profitability on a short-term or one- off basis are excluded. Attributable profit 34 Adjusted earnings per share ('EPSA') EPSA is a trend measure. The Group presents this measure to assist investors in their understanding of trends. Adjusted earnings per share is trading attributable profit divided by the weighted average number of shares outstanding. This is the same denominator used when calculating basic earnings per share. Basic earnings per share 34 Performance measures (continued) Trading cash flow Trading cash flow is used in conjunction with cash generated from operations to assess the conversion of trading profit into cash. It is key external metric used by the investor community and is a key performance measure for management. Trading cash flow is cash generated from operations excluding the impact of acquisition and disposal related items arising in connection with business combinations, including integration costs; restructuring events; and gains and losses resulting from legal disputes and uninsured losses. In addition to these items, gains and losses that materially impact the Group's cash flows on a short-term or one- off basis are excluded. Trading cash flow includes payment of capital element of lease liabilities, proceeds from disposal of property, plant and equipment and capital expenditure as presented in the Group cash flow statement. Cash generated from operations 34 Trading cash conversion This measure is used to assess the conversion of trading profit into cash. It is a key external metric Trading cash conversion is trading cash flow divided by trading profit. Cash generated from operations 34
Page 26
used by the investor community and is a key performance measure for management. Other measures Non-IFRS measure Purpose Definition Closest equivalent IFRS measure Reconciled on Free cash flow Free cash flow is a measure of the cash generated for the Group to use after capital expenditure according to its Capital Allocation Framework. This metric is used by both management and investor community. Free cash flow is net cash inflow from operating activities less capital expenditure, proceeds from disposal of property, plant and equipment and payment of lease liabilities. Net cash inflow from operating activities 35 Adjusted EBITDA Adjusted EBITDA is used in the calculation of adjusted leverage ratio. Adjusted EBITDA is attributable profit excluding taxation, share of results of associates, other finance costs, interest expense, interest income, acquisition and disposal related items, restructuring and rationalisation costs, amortisation and impairment of acquisition intangibles, legal and other costs, depreciation and impairment of property, plant and equipment and amortisation and impairment of other intangible assets. Attributable profit 36 Adjusted leverage ratio Adjusted leverage ratio is used in the calculation relating to debt covenants. We calculate adjusted leverage ratio by dividing net debt by adjusted EBITDA. Net debt is defined as total borrowings less cash and cash equivalents in the statement of financial position. Total borrowings include bank overdrafts, borrowings, loans and lease liabilities and long-term borrowings and lease liabilities. Leverage ratio (using IFRS measures) 36 Adjusted return on invested capital ('Adjusted ROIC') Adjusted ROIC is a metric used by investor community and is a measure of the return generated on capital invested by the Group. It provides a metric for long- term value creation and encourages compounding reinvestment within the business and discipline around acquisitions with low returns and long payback. Adjusted ROIC is a key performance measure under the Performance Share Program. Adjusted ROIC is defined as operating profit (before amortisation and impairment of acquisition intangibles) less adjusted taxes/((opening net operating assets + closing net operating assets)/2). Return on invested capital ('ROIC') (using IFRS measures) n/a Underlying revenue Reported revenue growth, the most directly comparable financial measure calculated in accordance with IFRS Accounting Standards as issued by the International Accounting Standards Board (IASB), reconciles to underlying revenue growth as follows: Reconciling Items 27 June 28 June Reported Underlying Acquisitions Currency 2026 2025 growth growth & disposals impact $m $m % % % % Segment revenue Sports Medicine & ENT 1,017 923 10.2 7.7 - 2.5 Advanced Wound Management 867 845 2.6 (0.1) - 2.7 Orthopaedics 1,213 1,193 1.7 (0.1) - 1.8 Revenue 3,097 2,961 4.6 2.3 - 2.3 Cash Profit generated Operating before Attributable from Earnings profit1 tax2 Taxation3 profit4 operations5 per share6 $m $m $m $m $m ¢ Half year 2026 Reported 448 380 (77) 303 605 35.6
Page 27
Acquisition and disposal related items 21 35 (6) 29 20 3.6 Restructuring and rationalisation costs 23 24 (6) 18 24 2.1 Amortisation and impairment of acquisition intangibles 87 87 (19) 68 7 8.1 Legal and other7 (13) (19) 5 (14) - (1.7) Lease liability payments - - - - (29) - Capital expenditure - - - - (190) - Proceeds from disposal of property, plant and equipment - - - - - - Half year 2026 Non-IFRS 566 507 (103) 404 437 47.7 Cash Profit generated Operating before Attributable from Earnings profit1 tax2 Taxation3 profit4 operations5 per share6 $m $m $m $m $m ¢ Half year 2025 Reported 429 362 (69) 293 568 33.5 Acquisition and disposal related items 9 20 (4) 16 7 1.8 Restructuring and rationalisation costs 8 8 (2) 6 52 0.6 Amortisation and impairment of acquisition intangibles 83 83 (19) 64 - 7.3 Legal and other7 (6) (4) 1 (3) 12 (0.3) Lease liability payments - - - - (25) - Capital expenditure - - - - (139) - Proceeds from disposal of property, plant and equipment - - - - 12 - Half year 2025 Non-IFRS 523 469 (93) 376 487 42.9 1 Represents a reconciliation of operating profit to trading profit. 2 Represents a reconciliation of profit before tax to trading profit before tax. 3 Represents a reconciliation of reported tax to trading tax. 4 Represents a reconciliation of reported attributable profit to trading attributable profit. 5 Represents a reconciliation of cash generated from operations to trading cash flow. 6 Represents a reconciliation of basic earnings per ordinary share to adjusted earnings per ordinary share (EPSA). 7 The ongoing funding of defined benefit pension schemes that are closed to future accrual is not included in management's definition of trading cash flow as there is no defined benefit service cost for these schemes. Acquisition and disposal related items For the half year ended 27 June 2026, the charge included integration costs relating to the acquisition of Integrity Orthopaedics and prior year acquisitions. For the half year ended 28 June 2025, the charge included costs of integration for prior year acquisitions. Adjusted profit before tax for the half year ended 27 June 2026 and 28 June 2025 also excludes the remeasurement and discount unwind for contingent consideration. Restructuring and rationalisation costs For the half year ended 27 June 2026, these costs primarily relate to the efficiency and productivity elements of the 12-Point Plan and the Operations and Commercial Excellence programme. These costs primarily consist of severance, integration and dual running costs. For the half year ended 28 June 2025, these costs primarily relate to the efficiency and productivity elements of the 12-Point Plan and the Operations and Commercial Excellence
Page 28
programme. These costs primarily consist of severance, integration and dual running costs, partially offset by gains on disposal of property, plant and equipment. Adjusted profit before tax for the half year ended 27 June 2026 additionally excludes restructuring costs related to the Group's shareholding in Bioventus. Amortisation and impairment of acquisition intangibles For both the half years ended 27 June 2026 and 28 June 2025, charges relate to the amortisation and impairment of intangible assets acquired in material business combinations. Legal and other For the half year ended 27 June 2026, charges relate to legal expenses for ongoing metal- on-metal hip claims. These expenses were offset by a release of $21m in the provision that reflects the decrease in the present value of the estimated costs to resolve all other known and anticipated metal-on-metal hip claims. Trading profit before tax additionally excludes $8m gain relating to deferred compensation arrangements, partially offset by $1m of finance costs for the unwind of discount relating to the provision for metal-on-metal hip claims. For the half year ended 28 June 2025, charges relate to legal expenses for ongoing metal- on-metal hip claims. These expenses were offset by a release of $11m in the provision that reflects the decrease in the present value of the estimated costs to resolve all other known and anticipated metal-on-metal hip claims. Trading profit before tax additionally excludes $2m of finance costs for the unwind of discount relating to the provision for metal-on-metal hip claims. Free cash flow A reconciliation from net cash inflow from operating activities, the most comparable IFRS measure, to free cash flow is set out below: 27 June 28 June 2026 2025 $m $m Net cash inflow from operating activities 450 396 Capital expenditure (190) (139) Payment of lease liabilities (29) (25) Proceeds from disposal of property, plant and equipment - 12 Free cash flow 231 244 Adjusted leverage ratio The calculation of the adjusted leverage ratio is set out below. Adjusted leverage ratio is calculated using metrics similar to those used in the debt covenant calculation. 27 June 31 December 2026 2025 $m $m Net debt 3,019 2,759 Attributable profit for the period 635 625 Taxation 162 154 Share of results of associates (119) (113) Other finance costs 22 16 Interest expense 136 140 Interest income (23) (28) Acquisition and disposal-related items 44 32 Restructuring and rationalisation costs 62 47 Amortisation and impairment of acquisition intangibles 180 176 Legal and other 155 162 Depreciation of property, plant and equipment 340 335 Impairment and amortisation of other intangible assets and property, plant and equipment 75 61 Adjusted EBITDA1 1,669 1,607 Adjusted leverage ratio1 1.8 1.7
Page 29
1 Adjusted leverage ratio for the half year 2026 has been calculated based on adjusted EBITDA for the rolling 12 months ended 27 June 2026. Leverage ratio (using closest equivalent IFRS measures) The leverage ratio using closest equivalent IFRS measures is not based on measures used in the calculation of debt covenants and is not used by management internally. This measure is not used for the Company's covenant in its private placement debt. 27 June 31 December 2026 2025 $m $m Bank overdrafts, borrowings, loans and lease liabilities 573 150 Long-term borrowings and lease liabilities 3,212 3,177 Total borrowings 3,785 3,327 Attributable profit 635 625 Leverage ratio1 6.0 5.3 1 Leverage ratio for the half year 2026 has been calculated based on attributable profit for the rolling 12 months ended 27 June 2026. This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authorityto act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this informationmay apply. For further information, please contact rns@lseg.com or visit www.rns.com. RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the informationcontained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. Forfurther information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy. END